How should pediatric cholestasis be diagnosed and managed?

Diagnosis and Management of Pediatric Cholestasis

Early diagnosis of biliary atresia is the absolute priority in pediatric cholestasis, as Kasai portoenterostomy must be performed within the first 2 months of life to achieve 70% prolonged survival—delays beyond 3 months dramatically reduce success and lead to death before age 2 without transplantation 1.

Diagnostic Approach

Initial Evaluation - Timing is Critical

The diagnostic workup must immediately differentiate extrahepatic biliary obstruction (primarily biliary atresia) from intrahepatic cholestasis, as this distinction determines mortality outcomes.

Start with abdominal ultrasound to identify:

• Biliary tract abnormalities
• Mass lesions
• Gallbladder abnormalities (triangular cord sign suggests biliary atresia)
• Choledochal cysts 2

If ultrasound shows bile duct abnormalities:

• Use MRCP as the next step for non-invasive biliary tree visualization—it approaches ERCP accuracy without the 3-5% pancreatitis risk 2
• Reserve ERCP only when therapeutic intervention is needed
• Proceed to intraoperative cholangiography if biliary atresia is suspected 3

If imaging excludes extrahepatic obstruction, diagnose intrahepatic cholestasis and investigate causes:

Differential Diagnosis of Intrahepatic Cholestasis

The major categories include 2, 4:

Metabolic diseases:

• α-1-antitrypsin deficiency (check phenotype: ZZ or SZ indicates disease risk)
• Cystic fibrosis
• Galactosemia, tyrosinemia
• Fatty acid oxidation defects
• Peroxisomal disorders

Genetic bile transport defects:

• Progressive familial intrahepatic cholestasis (PFIC) - ABCB11, ABCB4, ATP8B1 mutations
• Disorders of bile acid biosynthesis and conjugation

Bile duct paucity:

• Alagille syndrome (JAG1 or NOTCH2 mutations) - look for cardiac defects (peripheral pulmonary stenosis), characteristic facies (broad forehead, pointed chin), butterfly vertebrae 5, 4
• Non-syndromic ductopenia

Other causes:

• Infections (bacterial, viral including CMV)
• Parenteral nutrition-associated cholestasis
• Idiopathic neonatal hepatitis

Diagnostic Testing Algorithm

1. Immediate laboratory evaluation:

   • Direct/conjugated bilirubin (cholestasis defined as >2-3 weeks of conjugated hyperbilirubinemia)
   • Alkaline phosphatase (unreliable in growing children—use gamma-glutamyl transferase instead) 6
   • AST, ALT, albumin
   • α-1-antitrypsin level AND phenotype (not level alone, as it's an acute phase reactant) 4

2. Genetic testing:

   • Next-generation sequencing panels identify definite or possible genetic diagnosis in 11% of cholestatic infants 7
   • Test for PFIC genes (ABCB11, ABCB4, ATP8B1), JAG1/NOTCH2 (Alagille), and metabolic disorders 4, 8
   • Whole exome sequencing when panel testing is non-diagnostic 3, 9

3. Emerging biomarkers:

   • Serum matrix metalloproteinase-7 shows excellent diagnostic performance for biliary atresia in Japanese cohorts 7

4. Liver biopsy:

   • NOT routinely recommended for Alagille syndrome prognosis or management 8
   • Indicated when diagnosis remains unclear after imaging and genetic testing
   • Requires ≥10 portal fields for adequate bile duct assessment 2
   • Look for bile duct paucity, ductular proliferation, portal fibrosis

Management

Biliary Atresia - Surgical Emergency

Kasai portoenterostomy within 60 days of life is the treatment of choice:

• Achieves prolonged survival in 70% when performed <2 months 1
• Success drops significantly after 3 months 1
• High-dose corticosteroids within 72 hours of Kasai are NOT recommended 5

Post-Kasai monitoring for transplant referral:

• Refer for liver transplant evaluation if total bilirubin >6 mg/dL beyond 3 months post-Kasai 5
• Consider evaluation if bilirubin 2-6 mg/dL 5
• Also refer for unmanageable portal hypertension or liver failure despite successful Kasai 1

Transplant outcomes in biliary atresia are excellent:

• 1-year survival: 93%
• 5-year survival: >85%
• Best outcomes of any pediatric transplant group 1
• Delaying transplant until age ≥6 years improves graft and patient survival 1

Progressive Familial Intrahepatic Cholestasis (PFIC)

Before cirrhosis develops:

• Partial external biliary diversion produces clinical, biochemical, and histological improvement in the majority 1

After cirrhosis or failed biliary diversion:

• Liver transplantation required for long-term survival 1

New medical therapy:

• IBAT inhibitors (ileal bile acid transporter inhibitors) are FDA-approved for cholestatic pruritus in PFIC 10, 11
• Reduce serum bile acids and pruritus with minimal side effects
• May prolong native liver survival 10, 11

Alagille Syndrome

Medical management:

• IBAT inhibitor treatment should be offered for cholestatic pruritus 8
• Maralixibat and odevixibat are FDA-approved options 10, 11
• Consider partial external biliary diversion or ileal exclusion for intractable pruritus and xanthomas before transplant 5

Pre-transplant assessment:

• Mandatory cardiac evaluation for congenital heart disease (peripheral pulmonary stenosis, tetralogy of Fallot) 1, 5
• Assess for vascular anomalies: cerebral aneurysms, internal carotid narrowing, abdominal coarctation, renal artery stenosis 5
• Repair coarctation or renal artery stenosis BEFORE transplant 5

Transplant considerations:

• 5-year graft survival 61.5% vs 70% for biliary atresia (worse outcomes) 5
• Neurological and cardiac complications are risk factors for poor outcome 5
• Set realistic expectations about growth—short stature often persists post-transplant 1, 5

Supportive Care for All Cholestatic Children

Nutritional management:

• Aggressive nutritional support pre-transplant improves outcomes 5
• Fat-soluble vitamin supplementation (A, D, E, K)
• Medium-chain triglyceride formulas
• Caloric supplementation to achieve catch-up growth

Pruritus management:

• First-line: IBAT inhibitors (maralixibat, odevixibat) 8, 10, 11
• Alternative: bile acid-binding resins (cholestyramine)
• Ursodeoxycholic acid has NOT shown survival benefit in PSC and should not be used routinely 6

Portal hypertension:

• Beta-blocker use for primary prophylaxis remains controversial in children 5
• Manage variceal hemorrhage as it occurs
• May prompt transplant evaluation

Critical Pitfalls to Avoid

1. Never delay Kasai beyond 2 months - this is the single most important mortality determinant 1

2. Don't rely on alkaline phosphatase in children - it's normally elevated during growth; use gamma-glutamyl transferase instead 6

3. Don't check α-1-antitrypsin level alone - must include phenotype, as levels rise with inflammation 4

4. Don't perform routine liver biopsies in genetically-confirmed Alagille syndrome - insufficient data support prognostic value 8

5. Don't miss cardiac evaluation in Alagille syndrome - congenital heart disease is common and affects surgical risk 1, 5

6. Don't use high-dose corticosteroids after Kasai - no benefit demonstrated 5